Published in Cancer on October 01, 1994
Clinical Predictors of Survival for Patients with Stage IV Cancer Referred to Radiation Oncology. PLoS One (2015) 2.02
Prognostic factors among cancer patients with good performance status screened for phase I trials. Invest New Drugs (2007) 1.44
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res (2012) 1.29
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer (2003) 1.25
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. Invest New Drugs (2009) 1.12
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. Br J Cancer (2012) 1.06
Nurse and physician inter-rater agreement of three performance status measures in palliative care outpatients. Support Care Cancer (2009) 1.01
Associations among awareness of prognosis, hopefulness, and coping in patients with advanced cancer participating in phase I clinical trials. Support Care Cancer (2003) 1.00
Timing of palliative care referral and symptom burden in phase 1 cancer patients: a retrospective cohort study. Cancer (2010) 0.88
Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. J Cancer Res Clin Oncol (2010) 0.79
Validation of the Cochin Risk Index Score (CRIS) for life expectancy prediction in terminally ill cancer patients. Support Care Cancer (2011) 0.77
Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients. Clin Epigenetics (2016) 0.75
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol (1995) 5.86
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12
Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem (1999) 3.95
Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J (1998) 3.63
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist (2000) 3.62
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther (2012) 3.15
The mortality of elder mistreatment. JAMA (1998) 3.11
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol (1998) 3.06
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol (2002) 2.87
Analysis of environmental determinants of aggression and disruption in mentally retarded children. Appl Res Ment Retard (1986) 2.80
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J (2002) 2.77
New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol (1999) 2.76
Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol (1998) 2.69
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 2.66
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia (2006) 2.66
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest (1998) 2.62
Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol Cell Biol (2000) 2.61
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia (2003) 2.60
A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. JAMA (1993) 2.60
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst (1993) 2.57
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood (2000) 2.53
Risk factors for reported elder abuse and neglect: a nine-year observational cohort study. Gerontologist (1997) 2.41
Effectiveness of brief time-out with and without contingent delay: a comparative analysis. J Appl Behav Anal (1986) 2.36
The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. Proc Natl Acad Sci U S A (1996) 2.32
Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ (2001) 2.23
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest (1998) 2.18
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood (2001) 2.14
Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA (1991) 2.12
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med (2001) 2.09
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med (1993) 2.09
Thallium-201 single-photon emission CT versus CT for the detection of recurrent squamous cell carcinoma of the head and neck. AJNR Am J Neuroradiol (1999) 2.06
Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet (1981) 2.06
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma (2002) 2.04
Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid. Leuk Lymphoma (1994) 2.04
Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol (1997) 1.99
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Three-dimensional binary superlattices of magnetic nanocrystals and semiconductor quantum dots. Nature (2003) 1.94
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther (1999) 1.94
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res (2000) 1.93
ERV3, a full-length human endogenous provirus: chromosomal localization and evolutionary relationships. Virology (1984) 1.92
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood (1998) 1.91
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer (1999) 1.90
Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther (2007) 1.90
Oral chemotherapy: rationale and future directions. J Clin Oncol (1998) 1.88
Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol (1999) 1.81
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol (2001) 1.81
Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am (1997) 1.80
Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction (2004) 1.74
Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol (2000) 1.74
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res (2001) 1.72
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res (1994) 1.72
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res (2001) 1.71
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
Treatment of myelogenous leukemia: current status and investigational options. Blood (1996) 1.70
Characterization of the WIDR: a human colon carcinoma cell line. In Vitro (1979) 1.69
Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol (1999) 1.69
Helix handedness of Leptospira interrogans as determined by scanning electron microscopy. J Bacteriol (1979) 1.63
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB (2001) 1.62
Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer (1997) 1.57
Emergency medicine resident work productivity in an academic emergency department. Acad Emerg Med (2000) 1.57
Movement of antibody-coated latex beads attached to the spirochete Leptospira interrogans. Proc Natl Acad Sci U S A (1981) 1.56
Structure, tissue distribution and genomic organization of the murine RRM-type RNA binding proteins TIA-1 and TIAR. Nucleic Acids Res (1996) 1.56
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol (2000) 1.56
Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood (1999) 1.55
Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther (2012) 1.55
Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood (1994) 1.53
The use of a posterior lip augmentation device for a revision of recurrent dislocation after primary cemented Charnley/Charnley Elite total hip replacement: results at a mean follow-up of six years and nine months. J Bone Joint Surg Br (2007) 1.52
Management of hospital outbreaks of gastro-enteritis due to small roundstructured viruses. J Hosp Infect (2000) 1.52
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol (1999) 1.51
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol (1998) 1.51
Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk Res (2001) 1.51
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol (1996) 1.49
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia (2012) 1.49
Septic arthritis after arthroscopic anterior cruciate ligament reconstruction. Diagnosis and management. Am J Sports Med (1997) 1.49
Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med (1980) 1.48
High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant (2007) 1.48
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med (1995) 1.48
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest (1999) 1.47
Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med (1981) 1.47
99mTc-human serum albumin: an effective radiotracer for identifying sentinel lymph nodes in melanoma. J Nucl Med (1999) 1.46
Does application of Monsel's solution after loop diathermy excision of the transformation zone reduce post operative discharge? Results of a prospective randomised controlled trial. Br J Obstet Gynaecol (1992) 1.45
Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma (1993) 1.45
Cloning, characterization, expression, and chromosomal localization of a human ferritin heavy-chain gene. Proc Natl Acad Sci U S A (1986) 1.44
Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res (1996) 1.44
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst (1994) 1.44